Last reviewed · How we verify
hyaluronic acid 0.1%
Hyaluronic acid acts as a humectant and viscoelastic agent that hydrates and lubricates tissues by binding water and forming a protective barrier.
Hyaluronic acid acts as a humectant and viscoelastic agent that hydrates and lubricates tissues by binding water and forming a protective barrier. Used for Dry skin conditions, Skin hydration and moisturization, Topical wound care and tissue protection.
At a glance
| Generic name | hyaluronic acid 0.1% |
|---|---|
| Sponsor | University of Naples |
| Drug class | Humectant/Viscoelastic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid is a naturally occurring polysaccharide that binds large amounts of water, creating a hydrating and lubricating effect on skin and mucosal surfaces. At 0.1% concentration, it functions as a topical moisturizer and protective agent, reducing water loss from the stratum corneum and providing mechanical lubrication. This mechanism makes it useful for treating dry skin conditions and maintaining tissue hydration and comfort.
Approved indications
- Dry skin conditions
- Skin hydration and moisturization
- Topical wound care and tissue protection
Common side effects
- Local irritation or sensitization
- Allergic contact dermatitis
Key clinical trials
- XVIE to Treat Androgenetic Alopecia (AGA) (PHASE1, PHASE2)
- Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment (NA)
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- Regenarative Treatment of Periocular Wrinkles With PDRN (NA)
- Clinical Evaluation of Hyaluronic Acid and Platelet Rich Fibrin Injection Efficacy in Interdental Papilla Reconstruction (PHASE4)
- Clinical Study to Investigate a New Mouthwash in Reducing Plaque and Helping Prevent Gum Problems on Dental Implants Over a 6-month Period of Product Use (PHASE3)
- Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT (NA)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hyaluronic acid 0.1% CI brief — competitive landscape report
- hyaluronic acid 0.1% updates RSS · CI watch RSS
- University of Naples portfolio CI